WISTERIA

Wisteria Logo

A Phase I trial of WEE1 inhibition with Chemotherapy and Radiotherapy as adjuvant treatment, and a Window of Opportunity trial with Cisplatin in Patients with Head and Neck Cancer

Trial Overview and Summary


Chief Investigator: 
Professor Hisham Mehanna

 

Sponsor:
University of Birmingham

 

Funders: 
Cancer Research UK
AstraZeneca

 

Disease Site:
Head and Neck

 

Trial Type:
Clinical Trial of an Investigational Medicinal Product 

 

Status:
Closed

 

UKCRN Study ID:
32918

 

Open to New Sites?
No

 

Recruitment Start Date:
22 June 2017

 

Recruitment End Date:
31 October 2019

 

CRCTU Trial Management Team:
Early Drug Development Team

 

Trial Email Adress:
wisteria@trials.bham.ac.uk

 

Trial Summary

  • View Trial Summary Document [pdf 324 KB]

Head and neck cancer is the sixth most common cancer worldwide. Surgery followed by cisplatin chemotherapy and radiotherapy is currently the standard treatment offered. However, patients with head and neck cancer with high-risk features are at increased risk of relapse after surgery. Whilst chemo-radiotherapy improves cure rates, outcomes remain poor, and treatment has a significant impact on quality of life for these patients.

This study aims to see whether incorporating AZD1775 into the management of head and neck cancer offers the possibility of addressing these clinical issues. The purpose of the trial is to see whether it is safe and effective to combine a drug called AZD1775 with chemotherapy before surgery and with chemo-radiotherapy after surgery in treating patients with head and neck cancer. AZD1775 has been shown to increase the effect of cisplatin and of radiotherapy when tested in the laboratory. An approach that reduces the likelihood of requiring post-surgery treatment, and improves effectiveness of such treatment for those patients, who nevertheless require it, may best address the clinical problems set out above.

Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible.

Trial Protocol

Please Note:
Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to CancerHelp website (see the link below).

Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.

  • View Trial Protocol Document [pdf]

More Information